These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 19733066)
1. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727 [TBL] [Abstract][Full Text] [Related]
3. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236 [TBL] [Abstract][Full Text] [Related]
4. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. Zask A; Kaplan J; Verheijen JC; Richard DJ; Curran K; Brooijmans N; Bennett EM; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K J Med Chem; 2009 Dec; 52(24):7942-5. PubMed ID: 19916508 [TBL] [Abstract][Full Text] [Related]
5. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors. Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331 [TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404 [TBL] [Abstract][Full Text] [Related]
7. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities. Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206 [TBL] [Abstract][Full Text] [Related]
8. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model. Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787 [TBL] [Abstract][Full Text] [Related]
9. Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. Finlay MR; Buttar D; Critchlow SE; Dishington AP; Fillery SM; Fisher E; Glossop SC; Graham MA; Johnson T; Lamont GM; Mutton S; Perkins P; Pike KG; Slater AM Bioorg Med Chem Lett; 2012 Jun; 22(12):4163-8. PubMed ID: 22607682 [TBL] [Abstract][Full Text] [Related]
10. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha. Richard DJ; Verheijen JC; Yu K; Zask A Bioorg Med Chem Lett; 2010 Apr; 20(8):2654-7. PubMed ID: 20223664 [TBL] [Abstract][Full Text] [Related]
11. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970 [TBL] [Abstract][Full Text] [Related]
12. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors. Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129 [TBL] [Abstract][Full Text] [Related]
13. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors. Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367 [TBL] [Abstract][Full Text] [Related]
15. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors. Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143 [TBL] [Abstract][Full Text] [Related]
16. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658 [TBL] [Abstract][Full Text] [Related]
17. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401 [TBL] [Abstract][Full Text] [Related]
18. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Richard DJ; Verheijen JC; Curran K; Kaplan J; Toral-Barza L; Hollander I; Lucas J; Yu K; Zask A Bioorg Med Chem Lett; 2009 Dec; 19(24):6830-5. PubMed ID: 19896845 [TBL] [Abstract][Full Text] [Related]
19. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Verheijen JC; Yu K; Toral-Barza L; Hollander I; Zask A Bioorg Med Chem Lett; 2010 Jan; 20(1):375-9. PubMed ID: 19897362 [TBL] [Abstract][Full Text] [Related]